What clinical trial results support Mounjaro's effectiveness?
Large clinical trials have shown that Mounjaro (tirzepatide) leads to significant weight loss in adults with obesity or overweight, both with and without diabetes. In the SURMOUNT-1 and SURMOUNT-4 trials, people taking Mounjaro lost on average 15% to 21% of their body weight over about 9 to 18 months, compared to much smaller losses with placebo or standard care. These results led UK regulators to approve Mounjaro for weight management, highlighting its effectiveness beyond traditional diet and exercise alone.
- Mounjaro works by mimicking hormones that help regulate appetite, making people feel fuller with less food.
- In the SURMOUNT-1 trial (people without diabetes), average weight loss was 15% (5mg dose) to 20.9% (15mg dose) over 18 months, versus 3.1% with placebo.
- In the SURMOUNT-2 trial (people with type 2 diabetes), average weight loss was 12.8% to 14.7% (higher doses) over 18 months, versus 3.2% with placebo.
- In the SURMOUNT-4 trial, people lost on average 21% of their body weight in 36 weeks.
- The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and NICE have recognised these results as strong evidence for Mounjaro’s effectiveness for weight loss.
This text has been fact checked for accuracy by Alessandro Grenci, Superintendent Pharmacist at medino.